Skip to main content
Fig. 30 | Journal for ImmunoTherapy of Cancer

Fig. 30

From: 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Fig. 30

(Abstract P25). The xCELLigence platform uses impedance across resistor-coated plates to measure adherant tumor cell viability. Once 10,000 tumor cells became adherant and confluent, 1,000 T cells were added that expressed either a HER2 CAR only (H2) or a HER2 CAR with a truncated PD-1 protein (X), PD-1/CD28 protein (28), or PD-1/4-1BB protein (BB). Non-transduced T cells and tumor only wells served as controls

Back to article page